Sarepta Therapeutics Inc (SRPT) : Tang Capital Management added new position in Sarepta Therapeutics Inc during the most recent quarter end. The investment management firm now holds 250,000 shares of Sarepta Therapeutics Inc which is valued at $6,315,000 , the company said in a statement filed on Aug 15, 2016 with the SEC.Sarepta Therapeutics Inc makes up approximately 3.25% of Tang Capital Management’s portfolio.
Other Hedge Funds, Including , Mosaic Family Wealth boosted its stake in SRPT in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 1,600 shares of Sarepta Therapeutics Inc which is valued at $40,416. Sarepta Therapeutics Inc makes up approx 0.02% of Mosaic Family Wealth’s portfolio. Lord Abbett sold out all of its stake in SRPT during the most recent quarter. The investment firm sold 1,084,067 shares of SRPT which is valued $27,383,532. Hudson Bay Capital Management Lp added SRPT to its portfolio by purchasing 455,000 company shares during the most recent quarter which is valued at $11,493,300. Sarepta Therapeutics Inc makes up approx 1.12% of Hudson Bay Capital Management Lp’s portfolio. Cowen Prime Services sold out all of its stake in SRPT during the most recent quarter. The investment firm sold 2,500 shares of SRPT which is valued $65,900.
Sarepta Therapeutics Inc opened for trading at $25.89 and hit $26.63 on the upside on Thursday, eventually ending the session at $26.56, with a gain of 1.88% or 0.49 points. The heightened volatility saw the trading volume jump to 13,62,792 shares. Company has a market cap of $1,272 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $-1.21.Analysts expectations of $ .10.During the same quarter in the previous year, the company posted $-0.87 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Company shares were Reiterated by Needham on Jul 22, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $20 .Sarepta Therapeutics Inc was Upgraded by Piper Jaffray to ” Neutral” on Jun 9, 2016. Wedbush Upgraded Sarepta Therapeutics Inc on Jun 7, 2016 to ” Outperform”, Price Target of the shares are set at $36.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.